Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Formycon AG (FYB) Stock Price & Analysis

FYB Stock Chart & Stats

No data to display
Day’s Range
N/A
52-Week Range
N/A
Previous Close
N/A
Volume
N/A
Average Volume (3M)
N/A
Market Cap
CHF 308.03M
Enterprise Value
CHF 304.89M
Total Cash (Recent Filing)
CHF 51.78M
Total Debt (Recent Filing)
CHF 8.52M
Price to Earnings (P/E)
―
Beta
-0.19
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
-0.04
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong Balance Sheet

Low leverage and substantial equity provide Formycon with financial flexibility while it advances biosimilar programs. This reduces balance-sheet pressure over the next several quarters and offers greater capacity to fund development or absorb continued earnings volatility.

Improved Operating Cash Flow

The return to positive operating cash flow indicates that the underlying business generated cash from operations in 2025, an important improvement in internal funding capacity. If sustained, this could partially offset investment needs and reduce reliance on external financing.

Partner-Enabled Biosimilar Model

A portfolio of biosimilars spanning multiple therapeutic areas gives Formycon exposure to established biologic markets, while partners provide routes to commercialization. This model can broaden market access and support recurring product-related or partnering income as programs mature.

Bears Say

Recent Revenue Contraction

Two consecutive years of revenue contraction indicate that recent commercial or partnering income has not translated into sustained top-line growth. Persistent declines could reduce resources available for pipeline investment and make future revenue timing more dependent on successful program progression.

Deep Recent Losses

The shift from profits to deep losses demonstrates significant earnings volatility and weak recent operating performance. Continued losses could erode the equity cushion over time, constrain investment choices, and make the company more reliant on future product or milestone success.

Negative Free Cash Flow

Deeply negative and worsening free cash flow shows that investment and spending needs exceed cash generated after operating activity. If this pattern persists, Formycon may need additional funding, while ongoing cash burn could offset the protection provided by its currently strong balance sheet.

Formycon AG News

FYB FAQ

What is Formycon AG’s market cap?
Formycon AG’s market cap is CHF308.03M.
When is Formycon AG’s upcoming earnings report date?
Formycon AG’s next earnings report is estimated for Nov 12, 2026 (not yet confirmed), which is in 10 days.
How were Formycon AG’s earnings last quarter?
Formycon AG released its earnings results on Aug 12, 2026. The company reported -CHF0.766 earnings per share for the quarter, missing the consensus estimate of -CHF0.129 by -CHF0.637.
Is Formycon AG overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Formycon AG pay dividends?
Formycon AG does not currently pay dividends.
What is Formycon AG’s EPS estimate?
Formycon AG’s EPS estimate is -0.04.
How many shares outstanding does Formycon AG have?
Formycon AG has 17,672,928 shares outstanding.
What happened to Formycon AG’s price movement after its last earnings report?
Formycon AG reported an EPS of -CHF0.766 in its last earnings report, missing expectations of -CHF0.129. Following the earnings report the stock price went same ―.
Which hedge fund is a major shareholder of Formycon AG?
Currently, no hedge funds are holding shares in CH:FYB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology